Education
About Us
Working with TipRanks
Follow Us
TriSalus Life Sciences (TLSI)
NASDAQ:TLSI
Total Valuation
TriSalus Life Sciences has a market cap or net worth of $173.60M. The enterprise value is $153.14M.
Market Cap$173.60M
Enterprise Value$153.14M
Share Statistics
TriSalus Life Sciences has 31.28M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding31.28M
Owened by Insiders44.81%
Owened by Instutions4.10%
Financial Efficiency
TriSalus Life Sciences’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee$231,818.966
Profits Per Employee-$478,094.828
Employee Count116
Asset Turnover0.72
Inventory Turnover1.02
Valuation Ratios
The current PE Ratio of TriSalus Life Sciences is -1.34. TriSalus Life Sciences’s PEG ratio is >-0.01.
PE Ratio-1.34
PS Ratio4.29
PB Ratio-3.06
Price to Fair Value-3.06
Price to FCF-1.55
Price to Operating Cash Flow-1.59
PEG Ratio>-0.01
Income Statement
In the last 12 months, TriSalus Life Sciences had revenue of $26.89M and earned -$55.46M in profits. Earnings per share was -$4.68.
Revenue$26.89M
Gross Profit$23.42M
Operating Income-$42.72M
Pretax Income-$55.45M
Net Income-$55.46M
EBITDA-52.52M
Earnings Per Share (EPS)-4.68
Cash Flow
In the last 12 months, operating cash flow was -$43.98M and capital expenditures -$995.00K, giving a free cash flow of -$44.98M billion.
Operating Cash Flow-$43.98M
Free Cash Flow-$44.98M
Free Cash Flow per Share-$1.44
Dividends & Yields
TriSalus Life Sciences pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.02
52-Week Price Change-42.00%
50-Day Moving Average5.47
200-Day Moving Average4.97
Relative Strength Index (RSI)51.83
Average Volume (3m)62.84K
Important Dates
TriSalus Life Sciences upcoming earnings date is May 14, 2025, Before Open.
Last Earnings DateMar 27, 2025
Next Earnings DateMay 14, 2025
Ex-Dividend Date―
Financial Position
TriSalus Life Sciences as a current ratio of 1.42, with Debt / Equity ratio of -0.06
Current Ratio1.42
Quick Ratio1.25
Debt to Market Cap0.00
Net Debt to EBITDA―
Interest Coverage Ratio-3.38K
Taxes
In the past 12 months, TriSalus Life Sciences has paid $14.00K in taxes.
Income Tax$14.00K
Effective Tax Rate-0.02%
Enterprise Valuation
TriSalus Life Sciences EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
TriSalus Life Sciences has $11.29M in cash and marketable securities with $23.45M in debt, giving a net cash position of $12.16M billion.
Cash & Marketable Securities$11.29M
Total Debt$23.45M
Net Cash$12.16M
Net Cash Per Share$0.39
Tangible Book Value Per Share-$2.88
Margins
Gross margin is 85.93%, with operating margin of -292.53%, and net profit margin of -318.93%.
Gross Margin85.93%
Operating Margin-292.53%
Pretax Margin-318.89%
Net Profit Margin-318.93%
EBITDA Margin-314.94%
EBIT Margin-318.80%
Analyst Forecast
The average price target for TriSalus Life Sciences is $11.60, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$11.60
Price Target Upside110.53%
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast417.83%
EPS Growth Forecast-609.71%